Mylan announced that it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution, the generic version of Sunovion’s Xopenex ...

Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc. MARLBOROUGH, Mass., Sep 30, 2014 (BUSINESS WIRE) -- Sunovion Pharmaceuticals Inc. (Sunovion) ...

Teva Launches Generic Xopenex Concentrate Teva announced the launch of Levalbuterol Inhalation Solution, the generic version of Xopenex Inhalation Solution Concentrate. Teva announced the launch of ...

CINCINNATI, Ohio — Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer. Prasco said Monday that it had entered an ...

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic ...

Dr. Reddy’s Laboratories announced today that it has launched Levalbuterol Inhalation Solution in multiple dosage vials in the US market on Tuesday. It is a therapeutic equivalent generic version of ...

March 17, 2005 — The U.S. Food and Drug Administration (FDA) has approved a new indication for temozolomide, allowing its use in the first-line treatment of glioblastoma multiforme; orphan drug status ...

XOPENEX Inhalation Solution is available for use in a nebulizer at 0.31 mg and 0.63 mg dosage strengths for treatment of children 6 to 11 years old, and in 0.63 mg and 1.25 mg dosage strengths for ...

Co confirms that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL. On July ...

Watson Pharmaceuticals has launched an authorized generic version of Xopenex (levalbuterol HCl) Inhalation Solution. This is part of an agreement Watson has with Sunovion Pharmaceuticals, who ...